ArticleAnalytica chimica acta2004
Tunable plasmonic glucose sensing based on the dissociation of Con A-aggregated dextran-coated gold colloids.
Article in Analytica chimica acta, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 64 citations in OpenAlex.
- A High-Linearity Glucose Sensor Based on Silver-Doped Con A Hydrogel and Laser Direct Writing.Polymers · 2023Article
- Article
- MRI-based Glucose Assay Using Magnetic Nanoparticle Sensors.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021Article
- Magnetic nanoparticles incorporation into different substrates for dyes and heavy metals removal-A Review.Environmental science and pollution research international · 2020Review
- Angular-ratiometric plasmon-resonance based light scattering for bioaffinity sensing.Journal of the American Chemical Society · 2005Article
- Saccharide sensing using gold and silver nanoparticles--a review.Journal of fluorescence · 2004Review
- Size-dependent cellular toxicity and uptake of commercial colloidal gold nanoparticles in DU-145 cells.Cancer nanotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
We describe a new approach for glucose determination with tunable glucose dynamic sensing ranges, dependent on the properties of new nanosensors, which are comprised of Con A-aggregated dextran-coated gold colloids. Dextran-coated 10 or 20 nm gold colloids can be aggregated with Con A in a controlled fashion, the change in absorbance at an arbitrary wavelength used to monitor the extent of aggregation, which can be optimized for sensing. The presence of any glucose competitively binds with Con A, dissociating the dextran-coated colloids, affording for the reverse gold plasmon change and hence the determination of glucose concentrations. For one of our sensor systems, a 500K dextran-20 nm gold sensor, crosslinked with 8.70 µM Con A, a change in absorbance at 650 nm of 0.03 was observed, in response to as little as 3 mM glucose. In contrast, a 500K dextran-10 nm gold 18.7 µM Con A aggregate sensor, produced a 0.05 and 0.1 change in absorbance, respectively, by the addition of 50 and 100 mM glucose. We have found that the glucose sensing ranges can be somewhat tuned by altering the properties, and therefore the extent of aggregation of the gold aggregate sensors. Reducing the gold colloid size and dextran molecular weight typically reduces the glucose sensing range (lower [glucose]) but also reduces the long-term stability of the gold aggregate sensor. Similarly the concentration of Con A used to aggregate the system also has an effect on long term sensor stability and glucose response. In this paper, we present our findings, which offer unique opportunities and perspectives for building tunable plasmonic type glucose sensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.